Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | NQO2 | P16083 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | CCNK | O75909 | 1/20 | 0.36 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.36 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.36 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.36 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23479821 | 0.80 | DYRK1A (0.37) | PDE3BPDE3ALMNADYRK1ARXFP1 | |
| SCHEMBL17531158 | 0.80 | PDE3B (0.56) | GAACYP1A2HPGDPDE3BPDE3A | |
| SCHEMBL30480853 | 0.79 | ATAD2 (0.49) | CYP1A2PDE3BPDE3ALMNARXFP1 | |
| SCHEMBL6684317 | 0.77 | DYRK1A (0.36) | PDE3BPDE3ALMNADYRK1AMAPT | |
| SCHEMBL21603416 | 0.77 | PDE3B (0.53) | GAACYP1A2HPGDPDE3BPDE3A | |
| SCHEMBL23474457 | 0.77 | KEAP1 (0.43) | GAACYP1A2HPGDPDE3BPDE3A | |
| SCHEMBL8140613 | 0.77 | FYN (0.53) | GAACYP1A2PDE3BPDE3ARXFP1 | |
| SCHEMBL22641204 | 0.77 | PDE3B (0.41) | PDE3BPDE3ADYRK1ABRD4 | |
| SCHEMBL29301807 | 0.77 | DHFR (0.42) | PDE3BPDE3ALMNADYRK1ARXFP1 | |
| SCHEMBL3207779 | 0.74 | ALDH1A1 (0.42) | GAACYP1A2HPGDPDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312481-A1 | SUBSTITUTED (PHTHALAZIN-1-YLMETHYL)UREAS, SUBSTITUTED N-(PHTHALAZIN-1-YLMETHYL)AMIDES, AND ANALOGUES THEREOF | ARBUTUS BIOPHARMA CORP (CA) | 2023-10-05 | — | — | US | disclosed |
| US-20230312481-A1 | SUBSTITUTED (PHTHALAZIN-1-YLMETHYL)UREAS, SUBSTITUTED N-(PHTHALAZIN-1-YLMETHYL)AMIDES, AND ANALOGUES THEREOF | ARBUTUS BIOPHARMA CORP (CA) | 2023-10-05 | — | — | US | disclosed |
| WO-2021113698-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2021-06-10 | — | — | WO | disclosed |
| WO-2021113686-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2021-06-10 | — | — | WO | disclosed |
| WO-2021113682-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2021-06-10 | — | — | WO | disclosed |
| WO-2013010880-A1 | NEW CRTH2 ANTAGONISTS | ALMIRALL, S.A. (ES) | 2013-01-24 | — | — | WO | disclosed |
| EP-2548876-A1 | New CRTh2 antagonists | Almirall, S.A. (ES) | 2013-01-23 | — | — | EP | disclosed |
| EP-2526945-A1 | New CRTH2 Antagonists | Almirall, S.A. (ES) | 2012-11-28 | — | — | EP | disclosed |
| EP-2526945-A1 | New CRTH2 Antagonists | Almirall, S.A. (ES) | 2012-11-28 | — | — | EP | disclosed |
| US-20080027092-A1 | 1-Acetic Acid-Indole, -Indazole and -Benzimidazole Derivatives Useful for the Treatment of Respiratory Disorders | ASTRAZENECA AB (SE) | 2008-01-31 | — | — | US | disclosed |
| WO-2005121141-A1 | PYRROLOPYRIDINE DERIVATIVES AND USE THEREOF FOR TREATING DISEASES MEDIATED BY PROSTAGLANDIN D2 (PGD2) | OXAGEN LIMITED (GB) | 2005-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027092-A1 | 1-Acetic Acid-Indole, -Indazole and -Benzimidazole Derivatives Useful for the Treatment of Respiratory Disorders | IDO1, ABAT, ECI1 | GAA 732/4885CYP1A2 64/4885HPGD 196/4885 |
| US-20230312481-A1 | SUBSTITUTED (PHTHALAZIN-1-YLMETHYL)UREAS, SUBSTITUTED N-(PHTHALAZIN-1-YLMETHYL)AMIDES, AND ANALOGUES THEREOF | NSD3, PML, NSD1 | GAA 2522/4885CYP1A2 3133/4885HPGD 1773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.